Pfizer Just Beat Earnings and Raised Guidance—But the $650 Million Charge and the New CFO Tell the Real Story

 

Pfizer Just Beat Earnings and Raised Guidance—But the $650 Million Charge and the New CFO Tell the Real Story

**By [moonlight editory team ] | November 3, 2026 | 11-Minute Read**

---

## The Short Version (For the Busy American)

Pfizer just delivered a quarter that looks like a comeback, and the market's reaction was a collective shrug.

The pharmaceutical giant reported **adjusted earnings of 87 cents per share**, crushing the 73-cent consensus. Revenue hit **$16.58 billion**, beating the $15.87 billion estimate by roughly 4.6% . The company raised its full-year revenue guidance to **$62 billion to $64 billion**—up from $60.5 billion to $62.5 billion—and lifted its adjusted profit outlook to **$2.95 to $3.05 per share** .

But here's what the headline doesn't tell you: **revenue was flat year-over-year**. The growth came from newer products—cancer drugs, blood thinners, migraine treatments—offsetting the collapse of Pfizer's COVID franchise. And the company took a **$650 million charge** tied to a licensing deal with Chinese drugmaker Innovent Biologics, shaving 10 cents off earnings .

**The punchline:** Pfizer is winning the battle to replace its COVID revenue, but it's losing the war against its own margins. The stock barely moved on the beat—and that tells you everything about how much faith Wall Street has left in this turnaround.

---

## What Actually Happened: The Quarter Behind the Beat

Let me walk you through the numbers, because the composition matters more than the headline.

### The Beat

| Metric | Q3 2026 | Consensus | Beat |

|--------|---------|-----------|------|

| **Adjusted EPS** | **$0.87** | $0.73 | **+19.3%** |

| **Revenue** | **$16.58B** | $15.87B | **+4.6%** |

| **Net Income** | $3.24B | — | — |

| **Reported EPS** | $0.56 | — | — |

*Source: CNBC, TipRanks, LSEG* 

The adjusted EPS beat was substantial. The revenue beat was solid. But the **operating margin fell to 20.4%** from 35.3% a year earlier—a 13.5 percentage point decline that reflects the cost of restructuring and the loss of high-margin COVID sales .

### The Growth Engine

Here's the part that matters for Pfizer's future. **Non-COVID product revenue grew 7% operationally**, and the company's "launched and acquired products"—the newer drugs that are supposed to replace the COVID franchise—**surged 32%** .

The specifics are impressive:

- **Eliquis** (blood thinner): **$2.52 billion**, up 25%

- **Padcev** (cancer drug): **$720 million**, up 55%

- **Vyndaqel** (heart disease): **$1.77 billion**, up 12%

- **Nurtec** (migraine): **$547 million**, up 33%

- **Lorbrena** (lung cancer): **$387 million**, up 43% 

These are the drugs Pfizer is betting on to carry it through the patent cliff. And they're delivering.

### The COVID Drag

The problem is what they're replacing. **Comirnaty** (the COVID vaccine) generated **$808 million**, down sharply from its pandemic peak. **Paxlovid** (the antiviral) brought in **$449 million** . Both beat analyst expectations, but they're a shadow of what they once were.

The primary care division, which houses the COVID products, saw revenue **fall 9%** . That's the hole the newer drugs are trying to fill.

### The Innovent Charge

The **$650 million charge** tied to Pfizer's licensing deal with **Innovent Biologics**, a Chinese cancer drugmaker, is a one-time hit. It's part of Pfizer's strategy of buying up pipeline assets to replenish its portfolio. The charge shaved 10 cents off adjusted earnings, but it's a cash outlay for future growth, not a deterioration of the current business .

---

## The New CFO: A Safe Pair of Hands

Let me introduce you to the person who'll be managing Pfizer's finances through this transition.

### Cecile Guegan

Pfizer's board unanimously appointed **Cecile Guegan** as Chief Financial Officer and Executive Vice President, effective **November 1, 2026**. She had served as interim CFO since August, when **Dave Denton** left to become Nike's CFO .

Guegan isn't an outsider. She's a **25-year Pfizer veteran** who has held finance leadership roles across the company's biopharmaceutical business. She's led long-term forecasting for key product portfolios, managed major acquisitions and integrations, and co-led a strategic initiative to identify new sources of growth .

CEO **Albert Bourla** praised her: **"Cecile is an exceptional finance leader who knows our company and industry deeply, and she has a proven track record of optimizing financial performance while fueling growth. Her more than 25 years of experience paired with her strategic vision will provide the financial rigor and focus this next chapter demands"** .

Guegan's own statement was telling: **"My focus remains on executing a disciplined approach to capital allocation while making targeted investments today to drive revenue growth later in the decade and beyond"** .

That's CFO-speak for: *We're going to keep spending on new drugs, but we're going to be careful about it*. Given Pfizer's $9.7 billion cost-cutting target through 2029, "disciplined" is the operative word .

---

## The Human Touch: What This Means for Patients and Investors

Let me put this in terms that actually connect to your life.

### If You Take Pfizer Drugs

The good news is that the drugs are working. Eliquis for blood clots. Padcev for cancer. Vyndaqel for a rare heart condition. Nurtec for migraines. These are life-changing medications for millions of Americans.

The concern is what happens next. Pfizer is spending billions to acquire new drugs and develop its own pipeline, but the patent cliff is real. Eliquis, one of Pfizer's biggest sellers, faces generic competition in the coming years. The newer drugs are growing, but they need to grow fast enough to fill the gap.

### If You Own Pfizer Stock

You've been patient. The stock is up roughly 20% over the past year, but it's still well below its pandemic-era highs. The dividend—yielding around **6.5%**—has been the main reason to hold.

The quarter didn't change the story. Pfizer is a company in transition, replacing high-margin COVID revenue with lower-margin (but still profitable) new drugs. The beat was real. The guidance raise was real. But the flat revenue and the margin compression are reminders that this is a **show-me story**.

### The Obesity Wildcard

Here's something to watch. Pfizer is developing an **obesity treatment**, and management highlighted progress on the program in the earnings release . The obesity drug market is dominated by Eli Lilly and Novo Nordisk, but Pfizer is trying to carve out a niche.

If Pfizer's obesity drug succeeds, it could be the catalyst that finally re-rates the stock. If it fails, the company is left with a portfolio of solid but unspectacular drugs—and a dividend that investors will keep collecting while they wait for something better.

---

## Frequently Asked Questions

### Did Pfizer beat earnings?

**Yes, decisively.** Adjusted EPS was **$0.87** vs. the **$0.73** consensus. Revenue was **$16.58 billion** vs. **$15.87 billion** expected. Both were solid beats .

### Why did Pfizer raise guidance?

The company cited **"strong year-to-date performance"** and ongoing cost cuts. Full-year revenue guidance was raised to **$62-64 billion** from $60.5-62.5 billion, and adjusted EPS guidance to **$2.95-$3.05** from $2.80-$3.00 .

### Who is the new CFO?

**Cecile Guegan**, a **25-year Pfizer veteran** who had served as interim CFO since August. She took over when Dave Denton left for Nike. The board unanimously appointed her to the permanent role effective November 1 .

### Why was revenue flat if the company beat?

Because **COVID product sales collapsed** and offset growth in other areas. Non-COVID revenue grew **7%**, and launched/acquired products surged **32%**, but the decline in Comirnaty and Paxlovid kept total revenue flat .

### What is the $650 million charge?

It's a one-time charge tied to Pfizer's licensing and collaboration agreement with **Innovent Biologics**, a Chinese cancer drugmaker. It shaved **10 cents per share** off adjusted earnings but is part of Pfizer's strategy to replenish its pipeline .

### Is Pfizer's dividend safe?

**Probably.** The company generates substantial cash flow and has a cost-cutting program targeting **$9.7 billion in net savings through 2029**. The dividend yield of roughly **6.5%** is attractive, but the payout ratio is high. Watch the free cash flow trajectory.

### Should I buy Pfizer stock?

I can't give personalized investment advice. What I can tell you is that **the stock is cheap relative to its history**, the dividend is generous, and the newer drugs are growing. But the margin compression is real, the patent cliff is approaching, and the market's muted reaction to the beat suggests that investors are waiting for more proof.

---

## The Path Forward: What to Watch

### The Obesity Program

Pfizer's obesity drug candidate is the biggest potential catalyst. Watch for clinical trial data and regulatory updates. If the drug works, it could transform Pfizer's growth trajectory. If it doesn't, the company is left with a solid but unexciting portfolio.

### The Cost-Cutting Execution

Pfizer is targeting **$9.7 billion in net savings through 2029**. Watch whether the company hits that target without sacrificing its pipeline investments. The margin compression in Q3 shows that cost cuts take time to flow through.

### The Eliquis Patent Cliff

Eliquis is one of Pfizer's biggest sellers, and it faces generic competition in the coming years. Watch for the timing of the patent expiration and whether Pfizer can replace the revenue with newer drugs.

### The Next Earnings Report

The Q4 report will show whether the guidance raise was justified. Watch for **revenue growth**, **margin improvement**, and any updates on the obesity program.

---

## Conclusion: The Quiet Turnaround

Here's what I want you to take away from Pfizer's quarter.

The company beat earnings. It raised guidance. It appointed a seasoned insider as CFO. It's growing its newer drugs at a impressive clip. By almost every measure, this was a good quarter.

But **the stock barely moved**. And that's the most important signal of all. Wall Street has heard this story before—the promise of a post-COVID turnaround, the hope that newer drugs will fill the gap, the dividend that keeps investors patient.

The difference this time is that the newer drugs are actually delivering. **Padcev up 55%. Eliquis up 25%. Nurtec up 33%.** These aren't hypotheticals. They're revenue.

Pfizer is still in transition. The COVID money is gone. The margins are compressed. The patent cliff is coming. But the company is building something new, drug by drug, quarter by quarter.

The market isn't convinced yet. But Pfizer is giving it reasons to be.

---

## Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or medical advice. The author is not a licensed financial advisor or physician. All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Readers should conduct their own research and consult with a qualified financial professional before making any investment decisions. Data and figures cited are accurate as of the date of publication but may change. The author holds no position in any securities mentioned.

---

**Tags:** #Pfizer #PFE #Q3Earnings #PharmaStocks #StockMarketToday #FinancialNews #MarketAnalysis #Investing #CecileGuegan #AlbertBourla #Eliquis #Padcev #Vyndaqel #Nurtec #COVID #Comirnaty #Paxlovid #Innovent #EarningsSeason #HealthcareInvesting #DividendStocks #ObesityDrugs #PatentCliff #CostCutting #GuidanceRaise #InvestmentStrategy #RiskManagement #BigPharma #DrugPricing #NYSE